Reply to the Reviewer/Editor.

Dear Respected Editor/Reviewer,

Good day

Thank you for your thoughtful and constructive feedback on our article titled "Fecal Calprotectin in Pediatric Gastrointestinal Diseases: Pros and Cons." We appreciate your positive assessment of our work's scope, structure, and readability, and we are committed to addressing the specific suggestions you have provided to improve the manuscript. All the changes were marked in red for easy tracking by the reviewer. The manuscript looks much better with these changes, and we tried to improve the language as much as possible. Thank you again for your precious assistance.

Here we are replying point by point:

Reviewer 1:

- This manuscript reviewed the role of fecal calprotectin in pediatric gastrointestinal diseases. The author has provided an extensive discussion on several aspects, such as calprotectin in systemic diseases and gastrointestinal disorders, and some pediatric gastrointestinal disorders. This is an interesting review, and the authors distilled the key points and pros and cons.

Our reply: Thank you very much for your inspiring comment.

However, I still have several questions and suggestions listed below. Please make an answer or revision.

- Fecal calprotectin levels may change in different gastrointestinal diseases. The author should provide a table describing the changes in expression levels of fecal calprotectin in different diseases, populations, publication time, and cited literature.

Our reply: We added Table 3, which discussed the different studies of FC in various GI disorders, describing the changes in expression levels of fecal calprotectin in different diseases, populations, publication times, and cited literature.

- It is recommended to use images to present calprotectin in a more vivid and readable manner.
Our reply: We added Figure 2, which represents the Fecal calprotectin structure.

- There is a large amount of stacked literature in some parts of this review, and it is recommended to be more concise.

Our reply: We tried our best to be more concise.

- Calprotectin is expressed differently in different diseases, but is it involved in the occurrence and development of certain gastrointestinal diseases? The author should discuss this.

Our reply: We added one section to discuss this point.

- The author should also discuss the reasons for the inconsistent expression of calprotectin in different diseases.

Our reply: We added one section. We also added Table 4 to summarize the factors that affect FC expression.

After completing these revisions, we believe our article has been even more valuable to the scientific community, providing a deeper understanding of the relationship between renal tubular acidosis and renal calcification in children. We genuinely value your feedback, which will help us enhance the quality and impact of our work.

Thank you for your time and consideration. We look forward to resubmitting the revised manuscript for your review.

Sincerely,
Professor Mohammed Al-Biltagi
Corresponding Author